FDA

Congestive heart failure
#Cardiovascular disease #FDA #Heart failure #Phase I trial #Sequana Medical #United States

FDA reviews IND for congestive heart failure treatment

Sequana Medical has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for its second-generation DSR product (DSR 2.0) for the treatment of congestive heart failure. Fluid accumulation in heart failure patients is caused by the retention of too much… Read More

#News #Regulatory

Hospital patient on ventilator
#Covid-19 #Covid-19 treatment #FDA #InflaRx #Monoclonal antibodies

FDA okays Gohibic for emergency use in Covid-19 patients

Gohibic (vilobelimab) has been granted an Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for the treatment of Covid-19 in hospitalised adults. The monoclonal anti-human complement factor C5a antibody should be initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or… Read More

#News #Trending News

FDA
#Drug approvals #FDA #Marketing approval authorisation #Regulatory #United States

The regulatory round-up: Eight key FDA decisions

The Food and Drug Administration (FDA) in the US has made several key drug decisions over the last few weeks. Here’s a summary. Orserdu (elacestrant), Stemline Therapeutics The first and only treatment specifically indicated for patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast… Read More

#Exclusive Content #Regulatory

#Chemotherapy #EpicentRx #FDA #Head and neck cancer #Oncology #Phase II trial

US FDA fast-tracks drug to prevent severe chemotherapy side effect

The US Food and Drug Administration (FDA) has granted Fast Track Designation to RRx-001 for the prevention/attenuation of severe oral mucositis in chemotherapy and radiation-treated head and neck cancer patients. The FDA also accepted the company’s Investigational New Drug (IND) application to initiate a follow-on Phase… Read More

#News #Regulatory

#Clinical trial #CRISPR #FDA #Gene editing #Gene therapy #In vivo #Intellia Therapeutics

FDA clears in vivo gene editing therapy for trials in US

The US Food and Drug Administration (FDA) has cleared Intellia Therapeutics’ Investigational New Drug (IND) application for NTLA-2002 for the treatment of hereditary angioedema (HAE).  Intellia is a clinical-stage genome editing company focused on developing potentially curative therapies using CRISPR-based technologies.   The decision will enable… Read More

#News #Regulatory #Trending News

Doctor vaccinating baby
#FDA #Immunology / Virology & Vaccines #Paediatric #Phase II trial #Pneumonia

Pneumococcal vaccine gets go-ahead for infant trial

The US Food and Drug Administration (FDA) has cleared Vaxcyte’s infant Investigational New Drug (IND) application for VAX-24, its 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD).  The company plans to initiate the infant Phase II study in the second… Read More

#News

Breast cancer treatment
#Antibody drug conjugate (ADC) #Breast cancer #Cancer research #FDA #Gilead Sciences #GlobalData #Oncology

ADC potential “standard of care” for some breast cancer patients

The FDA has granted expanded approval for Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) for patients with HR-positive/HER2-negative metastatic breast cancer who have received hormonal therapy and at least two additional therapies in the metastatic setting.  The drug is expected to become a standard of care for these patients,… Read More

#News #Trending News

Endometrial biopsy
#Cancer research #FDA #GSK #Immuno-oncology #Oncology #Phase I trial #Regulatory

Full FDA approval for endometrial cancer treatment

The US Food and Drug Administration (FDA) has granted full approval for Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by a US FDA-approved test.  The approval is for endometrial cancer that has progressed on or… Read More

#News #Regulatory

Demyelination of neuron
#FDA #Muscular dystrophy #Paediatrics #Rare disease #SynaptixBio

Treatment for leukodystrophy could be “revolutionary”

The US Food and Drug Administration (FDA) has granted Rare Paediatric Disease (RPD) Designation to SynaptixBio’s drug candidate for TUBB4a leukodystrophy – a genetic and debilitating condition which mainly affects babies and young children.  RPDs are designed to encourage the development of new drugs with high unmet… Read More

#Editor's Choice #News #Regulatory

#Endogena Therapeutics #FDA #Ophthalmology #Orphan drugs #Priority Review #Retinitis pigmentosa

FDA Fast Track Designation for retinitis pigmentosa treatment

The US Food and Drug Administration (FDA) has designated the investigation of Endogena Therapeutics’ EA-2353 for the treatment of retinitis pigmentosa (RP) as a Fast Track development programme.   Fast Track is a process designed to enable patients to benefit earlier from important new drugs for serious conditions. … Read More

#News

Bone marrow transplant operation
#Biologics / Biotechnology #Cell therapy #FDA #Graft vs Host Disease #Mesoblast #Transplant

“Off-the-shelf” cellular medicine resubmitted to the FDA

Mesoblast has resubmitted its biologics license application (BLA) to the US Food and Drug Administration (FDA) for approval of remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD).  Survival outcomes have not improved over the past two decades for the most severe… Read More

#News #Regulatory

Patient receiving dialysis treatment
#Chronic kidney disease (CKD) #FDA #GSK #Kidney disease

New oral option for anaemia of CKD approved in US

The US Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat) for the once-a-day treatment of anaemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months.   Jesduvroq is the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) approved… Read More

#News #Regulatory

#Animal models #Animal testing #Drug discovery #Drug safety #FDA #Regulatory

What does the FDA animal testing legislation mean for drug discovery? 

As of late December 2022, the US Food and Drug Administration (FDA) no longer needs drugs to be tested in animals to receive approval, according to legislation signed by President Joe Biden1 – the Modernization Act 2.0. This news has been shared widely as a landmark moment, especially in the eyes… Read More

#Business & Investment #Exclusive Content #Opinion #Regulatory #Trends & Analysis

Cancer cells
#Breast cancer #Cancer research #FDA #Gene mutation #Genetics / genomics #Menarini #Oncology #Stemline Therapeutics

FDA-approved therapy targets ESR1 mutations in breast cancer

The first and only treatment specifically indicated for patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer has been approved in the US.  The Food and Drug Administration (FDA) has approved Orserdu (elacestrant) for the treatment of postmenopausal women or adult men, with ER+,… Read More

#News #Regulatory

#AI / data analytics / healthtech / informatics #Digital solutions #Digital workflow #EMA #FDA #Regulatory

Quicker time to regulatory submission through improved data management

Listen to this article on the DDW Podcast: Robust digital workflows can reduce errors and time to compile data leading to greater transparency, faster reporting and help biopharmaceutical companies reach regulatory submission faster. Ken Forman, Senior Director of Product Strategy, IDBS explains. For many start-ups operating on… Read More

#Exclusive Content

Live disease
#FDA #Fibrosis #GlobalData #Intercept Pharmaceuticals #Liver disease #Regulatory #Trial data #United States

First drug for NASH under second FDA review

Intercept Pharmaceuticals’ obeticholic acid (OCA) could be first drug to be approved in the US for non-alcoholic steatohepatitis (NASH), according to analysts GlobalData.  The Food and Drug Administration (FDA) accepted the company’s resubmission of its new drug application (NDA) for OCA in patients with pre-cirrhotic liver fibrosis… Read More

#News #Regulatory